(Q33914361)

30 July 2017

1 reference

title

Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections (English)

1 reference

30 July 2017

0 references

1 reference

cytomegaloviral disease

1 reference

D Ormrod

1

1 reference

30 July 2017

L J Scott

series ordinal

2

1 reference

30 July 2017

C M Perry

series ordinal

3

1 reference

30 July 2017

publication date

1 April 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

59

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

839-863

1 reference

Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group

30 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059040-00013

Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059040-00013

Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059040-00013

Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir

21 January 2018

1 reference

12 December 2020

A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. The Valaciclovir International Study Group.

1 reference

12 December 2020

Risk factors for cytomegalovirus infection after human marrow transplantation

1 reference

12 December 2020

Pharmacokinetics of acyclovir after intravenous and oral administration.

1 reference

12 December 2020

Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance

1 reference

12 December 2020

Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy

1 reference

12 December 2020

Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.

1 reference

12 December 2020

Once-daily valacyclovir hydrochloride for suppression of recurrent genital herpes

1 reference

12 December 2020

A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis S

1 reference

12 December 2020

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

1 reference

12 December 2020

Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group

1 reference

12 December 2020

A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group

1 reference

12 December 2020

Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group

1 reference

12 December 2020

Quantitative effects of valacyclovir on the replication of cytomegalovirus (CMV) in persons with advanced human immunodeficiency virus disease: baseline CMV load dictates time to disease and survival. The AIDS Clinical Trials Group 204/Glaxo Wellcom

1 reference

12 December 2020

Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome

1 reference

12 December 2020

An epidemiologic study of herpes simplex virus type 1 and 2 infection in Japan based on type-specific serological assays

1 reference

12 December 2020

Coping and adjustment to genital herpes

1 reference

12 December 2020

Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands

1 reference

12 December 2020

Prevention and control of herpesvirus diseases. Part 1. Clinical and laboratory diagnosis and chemotherapy. A WHO meeting

1 reference

12 December 2020

Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.

1 reference

12 December 2020

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group

1 reference

12 December 2020

Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers

1 reference

12 December 2020

Impact of cytomegalovirus infection on organ transplant recipients

1 reference

12 December 2020

New antiherpesvirus agents. Their targets and therapeutic potential

1 reference

12 December 2020

Herpes simplex virus type 2 in the United States, 1976 to 1994.

1 reference

12 December 2020

Multiple interactions of cimetidine and probenecid with valaciclovir and its metabolite acyclovir

1 reference

12 December 2020

Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once daily therapy. International Valaciclovir HSV Study Group

1 reference

12 December 2020

Virus drug-resistance: mechanisms and consequences

1 reference

12 December 2020

Famciclovir and valaciclovir differ in the prevention of herpes simplex virus type 1 latency in mice: a quantitative study.

1 reference

12 December 2020

Valaciclovir: development, clinical utility and potential

1 reference

12 December 2020

Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line

1 reference

12 December 2020

Prevalence of herpes simplex virus infection in patients suspected of genital herpes; and virus typing by type specific fluorescent monoclonal antibodies.

1 reference

12 December 2020

Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation

1 reference

12 December 2020

Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy

1 reference

12 December 2020

Cytomegalovirus infections in transplant patients.

1 reference

12 December 2020

In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus

1 reference

12 December 2020

Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy

1 reference

12 December 2020

A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. Genival Study Group

1 reference

12 December 2020

Cytomegalovirus retinitis and low CD4+ T-lymphocyte counts

1 reference

12 December 2020

Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients

1 reference

12 December 2020

Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model

1 reference

12 December 2020

Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection.

1 reference

12 December 2020

Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial

1 reference

12 December 2020

Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group

1 reference

12 December 2020

Psychosocial implications of recurrent genital herpes simplex virus infection

1 reference

12 December 2020

Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients.

1 reference

12 December 2020

Safety of acyclovir: a summary of the first 10 years experience

1 reference

12 December 2020

Comparison of effects of famciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model

1 reference

12 December 2020

The Effect of Valaciclovir on Cytomegalovirus Viremia and Viruria Detected by Polymerase Chain Reaction in Patients with Advanced Human Immunodeficiency Virus Disease

1 reference

12 December 2020

Phase I trial of valaciclovir, the L-valyl ester of acyclovir, in patients with advanced human immunodeficiency virus disease

1 reference

12 December 2020

Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy

1 reference

12 December 2020

The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice

1 reference

12 December 2020

Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204).

1 reference

12 December 2020

Cytomegalovirus infection and indirect sequelae in the immunocompromised transplant patient

1 reference

12 December 2020

Antiviral drug susceptibility of human herpesvirus 8

1 reference

12 December 2020

1 reference

12 December 2020

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

1 reference

12 December 2020

Prevalence of antibodies to herpes simplex virus types 1 and 2, Epstein-Barr virus and cytomegalovirus in teenage girls

1 reference

12 December 2020

Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections

1 reference

12 December 2020

Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy

1 reference

12 December 2020

Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study

1 reference

12 December 2020

Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy

1 reference

12 December 2020

Antiviral therapies for long-term suppression of genital herpes

1 reference

12 December 2020

Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy

1 reference

12 December 2020

10.2165/00003495-200059040-00013

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1042062456

0 references

1 reference